Facebook
Linkedin
Twitter
Industries
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Quick Byte
Resources
Search
Friday, April 4, 2025
Facebook
Linkedin
Twitter
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
ReadMagazine
Industries
All
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
How Genomics is Reshaping Personalized Healthcare
Solera Unveils AI-Driven Fleet Management Platform
Culture Biosciences Unveils Stratyx™ 250: The First Cloud-Integrated, Mobile Bioreactor for…
PANTHERx® Rare Expands Patient Support Capabilities for Cell and Gene Therapies…
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Quick Byte
Resources
Home
Tags
BCMA/CD19
BCMA/CD19
Biotechnology
Gracell Biotechnologies Presents Updated Clinical Data for BCMA/CD19 Dual-targeting FasTCAR GC012F
PR Newswire
-
June 14, 2022
Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced the...
0
Fans
Like
3,912
Followers
Follow
0
Subscribers
Subscribe
Hot Topics
How Genomics is Reshaping Personalized Healthcare
Solera Unveils AI-Driven Fleet Management Platform
Culture Biosciences Unveils Stratyx™ 250: The First Cloud-Integrated, Mobile Bioreactor for Accelerated Cell Culture Development
Load more
